Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company AstraZeneca plc
DescriptionJanus kinase-1 (JAK-1) and Janus kinase-2 (JAK-2) inhibitor
Molecular Target Janus kinase-2 (JAK-2) ; Janus kinase-1 (JAK-1)
Mechanism of ActionJanus kinase-2 (JAK-2) inhibitor; Janus kinase-1 (JAK-1) inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I/II
Standard IndicationMyeloproliferative disorder
Indication DetailsTreat myelofibrosis
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today